Study Stopped
Insufficient numbers of Sino-implant users available for study participation.
Kenya Sino-implant (II) PK Study
A Pharmacokinetic Study to Compare Sino-implant (II) During Four Years of Use to Jadelle During Five Years of Use by Kenyan Women
1 other identifier
observational
N/A
1 country
1
Brief Summary
A cross-sectional study to compare pharmacokinetics of Sino-implant (II) during four years of used and Jadelle during five years of use by Kenyan women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 2013
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2013
CompletedFirst Posted
Study publicly available on registry
August 29, 2013
CompletedStudy Start
First participant enrolled
September 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedOctober 14, 2013
October 1, 2013
3 months
August 21, 2013
October 11, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Total and Free LNG concentrations in Jadelle users at Four Years and Sino-implant users at Five Years
Total and free LNG plasma concentrations measured at four years of Sino-implant (II)use and at five years of Jadelle use
6 months
Secondary Outcomes (3)
Total and Free LNG concentrations at Four Years of Jadelle and Sino-implant Use
6 months
Total and free LNG plasma concentration-time profiles at 4 years following Sino-implant (II) and at over 5 years following Jadelle insertion
6 months
SHBG serum concentration-time profile over 4 years following Sino-implant (II) and over 5 years following Jadelle insertion.
6 months
Study Arms (6)
Cohort 1
Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
Cohort 2
TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
Cohort 3
Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
Cohort 4
Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
Cohort 5
Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
Cohort 6
Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
Eligibility Criteria
Women between the ages of 18 and 44 who have received contraceptive implants from the Marie Stopes Kenya Eastleigh clinic and MSK mobile clinics in the Nairobi area.
You may qualify if:
- Have a Sino-implant (II) or Jadelle implant set in place, confirmed by physical exam;
- Have a confirmed contraceptive implant insertion date consistent with the criteria for the cohort she is to be enrolled in;
- Be aged between 18 and 44 years, inclusive;
- Not wish to become pregnant in the next six months;
- Not desire implant removal within the next six months.
- Be able to understand the information given to them and to make personal decisions on whether to participate or not in the study;
- Consent to participation, and sign an informed consent form;
- Agree and be able to return to the clinic for the second study visit.
You may not qualify if:
- Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's wort (Hypericum perforatum), by self-report;7
- Use of medications containing LNG or other hormones that impact LNG or SHBG disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances, by self-report;
- Use of anti-retroviral drugs, by self-report;
- Any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- FHI 360lead
- Marie Stopes Internationalcollaborator
Study Sites (1)
Marie Stopes Kenya Eastleigh Clinic
Nairobi, Kenya
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Ayallo, MD
Marie Stopes Kenya
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 21, 2013
First Posted
August 29, 2013
Study Start
September 1, 2013
Primary Completion
December 1, 2013
Study Completion
December 1, 2013
Last Updated
October 14, 2013
Record last verified: 2013-10